RxDoctor Payments Data

Maria Renna, MD

Geriatric Medicine · Wethersfield, CTNPI 1164750030

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 333 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,363, more than ten times the $227 reported in 2019. Among geriatric medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,241in general payments, 2019–2025

Across 333 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$956
  • Lilly USA, LLC$812
  • GSK$587
  • AbbVie$432
  • Novo Nordisk$379
  • Pfizer$332
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$6,232100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,241 in reported general payments places this provider in the 95th percentile of 84 geriatric medicine providers in Connecticut.

See all geriatric medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$107,281
Medicare patients
210
Services billed
2,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin178$221,704
FarxigaDapagliflozin Propanediol130$132,730
EliquisApixaban117$124,246
JanuviaSitagliptin Phosphate94$113,348
OzempicSemaglutide65$86,936
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$60,890
XareltoRivaroxaban44$31,299
InvokanaCanagliflozin13$28,786
TrulicityDulaglutide11$25,913
MyrbetriqMirabegron21$18,868
JanumetSitagliptin Phos/Metformin Hcl21$18,402
EntrestoSacubitril/Valsartan21$18,002
TrintellixVortioxetine Hydrobromide26$12,551
TradjentaLinagliptin15$11,479
Tresiba Flextouch U-100Insulin Degludec16$8,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$243$233,183193 claims
AstraZenecaFarxiga, Brilinta$956$138,865144 claims
MerckJanuvia, Janumet$69$131,750115 claims
PfizerEliquis$332$124,246117 claims
Novo NordiskOzempic$379$86,93665 claims
Johnson & JohnsonXarelto, Invokana, Concerta$16$68,55868 claims
GSKTrelegy Ellipta, Breo Ellipta$587$67,29997 claims
Lilly USA, LLCTrulicity$812$25,91311 claims
Astellas Pharma US IncMyrbetriq$248$18,86821 claims
NovartisEntresto$78$18,00221 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$113$12,55126 claims
AbbVieLinzess, Synthroid$432$12,36468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 84 geriatric medicine providers in Connecticut.

Other geriatric medicine in Wethersfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →